AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02251184
Drug: Aggrenox
RxNorm normalized name: Aggrenox
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02251184
Drug: Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01042522
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00793663
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
Trial: NCT00793663
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
Trial: NCT00793663
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous use, 4 mg, single shot
Trial: NCT02251184
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02251184
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00793663
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous use; single shot
Trial: NCT00793663
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous use; 4 mg; single shot
Trial: NCT00318812
Drug: Heme Iron Polypeptide (Proferrin)
RxNorm normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heme iron polypeptide 11mg po tid for 6 months
Trial: NCT00318812
Drug: Iron sucrose (Venofer)
RxNorm normalized name: iron sucrose Injection [Venofer]
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose infusion IV q month x 6 months
Trial: NCT00209469
Drug: alendronate sodium
RxNorm normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00725881
Drug: Trans sodium crocetinate (TSC)
RxNorm normalized name: trans-crocetin
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
Trial: NCT02287389
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01294202
Drug: AT13387 and Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib.
Trial: NCT00928525
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
Trial: NCT02372149
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02157636
Drug: CPI-0610
RxNorm normalized name: CPI-0610 anhydrous
DrugBank: Pelabresib anhydrous (DB17129)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00239278
Drug: budesonide/formoterol, 2x 200/6 microgram. 4 times daily
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04742283
Drug: Timolol Maleate Ophthalmic Solution 0.5% BID
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol Maleate Ophthalmic Solution BID (morning and evening)
Trial: NCT02567942
Drug: propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be anesthetized by using propofol infusion during operation
Trial: NCT02567942
Drug: sevoflurane group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be anesthetized by using sevoflurane inhalation during operation
Trial: NCT02424097
Drug: CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MI Paste \& MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray
Trial: NCT04262934
Drug: Cholecalciferol 100.000 UI administration
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral Administration - Every month
Trial: NCT01738373
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor will be prescribed independently by the physician, according to usual practice.
Trial: NCT01235143
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
Trial: NCT01235143
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
Trial: NCT00407524
Drug: AKL 1
RxNorm normalized name: Aklief
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00708123
Drug: Sodium fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
Trial: NCT04013919
Drug: Multiple Daily Injections of Insulin
RxNorm normalized name: insulin degludec Injectable Solution
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Basal/ Bolus insulin injections
Trial: NCT04013919
Drug: Single insulin injections
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin injections only
Trial: NCT01224860
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
Trial: NCT01224860
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
Trial: NCT00581139
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mg/kg oral midazolam
Trial: NCT02509806
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib Mesylate Tablets 500 mg qd p.o.
Trial: NCT03008850
Drug: MgSo4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.
Trial: NCT03827291
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
Trial: NCT03115736
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
Trial: NCT01675635
Drug: OxyNorm Capsules
RxNorm normalized name: oxycodone hydrochloride Oral Capsule [Oxynorm]
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
Trial: NCT03761095
Drug: Unesbulin
RxNorm normalized name: Unesbulin
DrugBank: Unesbulin (DB18080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unesbulin will be administered as per the dose and schedule specified in the arm.
Trial: NCT03761095
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine will be administered as per the dose and schedule specified in the arm.
Trial: NCT02374099
Drug: CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
Trial: NCT02374099
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
Trial: NCT01057407
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01868880
Drug: Ivabradine plus beta-blocker (bisoprolol)
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
Trial: NCT00388700
Drug: GM-CT-01
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
Trial: NCT00388700
Drug: 5-Fluorouracil, Leukovorin, bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
Trial: NCT01603355
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks
Trial: NCT00788333
Drug: BMS-754807
RxNorm normalized name: BMS-754807
DrugBank: BMS-754807 (DB15399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
Trial: NCT00788333
Drug: trastuzumab (Herceptin®)
RxNorm normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
Trial: NCT03219580
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
Trial: NCT01651039
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
Trial: NCT02904915
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
Trial: NCT01422122
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 mg per day, one tablespoon syrup per day
Trial: NCT00236808
Drug: levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00550680
Drug: Methoxy polyethylene glycol-epoetin beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
Trial: NCT00923130
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
Trial: NCT00923130
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
Trial: NCT04020601
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection
Trial: NCT04020601
Drug: Dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection
Trial: NCT03483753
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min
Trial: NCT01651039
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
Trial: NCT03790345
Drug: Cobalamin
RxNorm normalized name: Cobalamin
DrugBank: Cobalamin (DB14098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant daily treatment with 2mg of cobalamin
Trial: NCT02997150
Drug: IL-2 Low dose
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection
Trial: NCT03693625
Drug: GDC-0853
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Trial: NCT02258451
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
Trial: NCT02258451
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 25 mg tablet once daily after a meal.
Trial: NCT02258451
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice.
Trial: NCT01498003
Drug: tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
Trial: NCT01498003
Drug: normal saline solution
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same use as tirofiban
Trial: NCT04206332
Drug: VRC-MALMAB0100-00-AB
RxNorm normalized name: AB-8939
DrugBank: AB-8939 (DB17115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
Trial: NCT04124913
Drug: Dydrogesterone 10 MG Oral Tablet
RxNorm normalized name: dydrogesterone 10 MG Oral Tablet
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
Trial: NCT04124913
Drug: Progesterone Vaginal Gel [Crinone]
RxNorm normalized name: progesterone Vaginal Gel [Crinone]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal progesterone gel 90 mg once a day for luteal phase support
Trial: NCT00977522
Drug: PF-03463275
RxNorm normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Controlled Release tablet BID for 12 weeks
Trial: NCT00520923
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
Trial: NCT00520923
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Trial: NCT00520923
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Trial: NCT00520923
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Trial: NCT00520923
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
Trial: NCT04066491
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
Trial: NCT03988803
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet
Trial: NCT03988803
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film coated tablet
Trial: NCT04066491
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
Trial: NCT01053871
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conscious sedation using propofol
Trial: NCT00389792
Drug: ATI-2042
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no intervention
Trial: NCT00389792
Drug: ATI-2042 200 mg
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
Trial: NCT01805531
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.